Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Randomized, 4-Arm, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Conditions
Interventions
RT001 Botulinum toxin type A (Dose A)
RT001 Botulinum Toxin Type A (Dose B)
+2 more
Locations
1
United States
Dermatology Research Institute, LLC
Coral Gables, Florida, United States
Start Date
April 1, 2010
Primary Completion Date
July 1, 2010
Completion Date
July 1, 2010
Last Updated
January 30, 2014
NCT04818203
NCT06997380
NCT06657365
NCT06984432
NCT04985916
NCT06321770
Lead Sponsor
Revance Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions